Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands

Novo Nordisk A/S211 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.

Study Type

OBSERVATIONAL

Enrollment

211

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Prescription at the discretion of the treating physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetic subjects treated with BHI 30

Locations (1)

Novo Nordisk Investigational Site

Alphen aan den Rijn, Netherlands

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Number of hypoglycaemic events

Treatment satisfaction: ITSQ (Insulin Treatment Satisfaction Questionnaire)

Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.